

Francisco Campos Pérez

PLATMED

Biomimetic platelet-derived nanomedicines for treatment of thromboembolic stroke

Coordinator:



Francisco Campos Pérez, Health Research Institute of Santiago de Compostela (IDIS), Spain

Contact:

francisco.campos.perez@sergas.es

Partners:




Beatriz Pelaz, Universidade de Santiago de Compostela (USC)



Denis Vivien, University Caen-Normandy, GIP Cyceron



Dusica Maysinger: McGill University



Stroke is a disease that occurs unexpectedly and has a disastrous outcome. Approximately 15 million people will experience a stroke episode every year worldwide, of which 33% are left with a permanent disability, whereas 40% of cases will result in death.

Thrombolysis with intravenous recombinant tissue plasminogen activator (rtPA) is the only approved drug treatment for patients with acute ischemic stroke, but its use is limited by a narrow therapeutic window, selective efficacy, and haemorrhagic complications.

The main ambition of the PLATMED project is to fabricate a new model of “smart” nanomedicines in order to improve the thrombolytic efficacy of rtPA, reduce the risk of systemic bleeding and haemorrhage, and evaluate the recanalization rate by imaging techniques. This innovative strategy is expected to improve the outcome of rtPA-treated stroke patients, increase the therapeutic time-window, and thus the number of stroke patients that can benefit from this treatment.